An isotopic infusion technique has been used in an attempt to determine the contribution that local, in situ, oestrone synthesis makes to the oestrogen content of breast tumours. 3H-Androstenedione and 14C-oestrone were infused into women with advanced breast cancer for 12 hr before operation. At surgery, normal breast and breast tumour biopsy samples were obtained and 3H-androstenedione, 3H-oestrone derived from 3H-androstenedione and 14C-oestrone were isolated and measured. DNA polymerase alpha activity, a marker of cellular proliferation, was also measured to examine whether local synthesis of oestrone exerted a biological effect. The study was repeated after patients had been treated with the aromatase inhibitor, 4-hydroxyandrostenedione, before undergoing further surgery for removal of their tumours. In 4/6 tumours examined, in situ synthesis of 3H-oestrone from 3H-androstenedione accounted for the major part (84.3 +/- 9.0%) of the 3H-oestrone detected, while no significant in situ synthesis occurred in 2 other tumours. Although treatment with 4-hydroxyandrostenedione did not significantly alter the uptake of 3H-androstenedione or 14C-oestrone into breast tissues, in situ formation of 3H-oestrone was only detected in one tumour sample after treatment. DNA polymerase alpha activity decreased in 4/6 tumours after treatment with 4-hydroxyandrostenedione. Overall, however, there was no significant correlation between the level of 3H-oestrone formed in situ and DNA polymerase alpha activity (r = 0.38, NS). It is concluded that in some, but not all, breast tumours in situ formation of oestrone can make an important contribution to the oestrogen content of breast tumours.
Between February 1983 and April 1986 we studied peripheral blood and bone marrow samples from 20 patients with human immunodeficiency virus (HIV) related disease. 14 patients had AIDS, three had ARC, two had PGL and one had ITP as a sole manifestation of HIV related disease. Peripheral blood abnormalities included marked anisocytosis and poikilocytosis, rouleaux formation, neutropenia, lymphopenia, monocytopenia, a left shift in the granulocyte series and, in the patients with AIDS, vacuolated monocytes. The most frequent bone marrow abnormalities were reticuloendothelial iron block, dyserythropoiesis, megaloblastic change and erythroid hypoplasia. Excess histiocytes were noted in four marrows, one exhibiting haemophagocytosis. None of the bone marrows showed lymphopenia. Eight of the 20 marrows were difficult or impossible to aspirate. None of the trephine biopsies showed increased reticulin. The causes of these abnormalities are probably multiple and include opportunistic infections, drug therapy, immune mechanisms and possibly direct insult by the HIV virus.
Prostate-specific antigen (PSA) is a 33 kDa serine protease which is produced by many different tissues in the body and has been shown to be present in low concentrations in breast milk and in about 30% of breast cancers. The presence of PSA in breast cancers is associated with the presence of steroid-hormone receptors and may be a favourable prognostic indicator. In this study, PSA immunoreactivity was measured in breast cyst fluid obtained from women with palpable breast cysts which is the most common benign breast disease. PSA was found to be present in very low concentrations in breast cyst fluid. In an attempt to understand the possible role of PSA in the breast, the effect of PSA on growth of the hormone-dependent MCF-7 and hormone-independent MDA-MB-231 human breast cancer cell lines was studied. In addition, the effect of PSA on oestrone sulphatase activity and oestrogen 17-oxidoreductase activity in these cell lines was investigated. PSA, in low concentrations, was found to inhibit MCF-7 cell growth and to stimulate the conversion of oestradiol to the less potent oestrogen oestrone in this cell line. PSA had no effect on the MDA-MB-231 cell line. Our findings suggest that PSA may act as a negative growth regulator in hormone-dependent breast cancers.
The detection and diagnosis of pheochromocytoma are highly dependent on the biochemical confirmation of excessive catecholamine release by the tumor. As the reliability of baseline plasma catecholamines in the detection of pheochromocytoma is questionable, assessment of the excretion rates of catecholamines or metabolites in 24-h urine collections remains the mainstay of initial biochemical investigation. However, diagnostic difficulties can arise from incomplete collection of 24-h specimens or equivocal increases in catecholamines due to stress. To investigate the diagnostic validity of shorter collection times for the biochemical detection of this tumor, we measured the excretion of catecholamines and metabolites after sleep, a period associated with decreased sympathetic activity. Overnight catecholamines, metanephrines, and 4-hydroxy-3-methoxymandelic acid (HMMA) levels were measured in 16 patients with histologically confirmed pheochromocytomas, 166 patients with hypertension, and 24 normotensive subjects. All measurements were performed by high performance liquid chromatography with electrochemical detection. Overnight excretion of norepinephrine in the tumor group (range, 86-1552 nmol/mmol creatinine) was significantly different (P <0.001) from that in the nontumor group (14-63 nmol/mmol creatinine). Autonomous secretion of norepinephrine was evident in all urine collections, including a patient with a predominantly epinephrine-secreting tumor. Overnight normetanephrine levels displayed a similar excretion pattern (P < 0.001), whereas overnight epinephrine and metanephrine levels were normal in 10 of the 16 patients with pheochromocytoma. In contrast, HMMA excretion in overnight urine collections was highly variable, with only 6 of the 16 patients in the tumor group having consistently elevated excretion. In the other 10 patients, overnight HMMA excretion showed a high intravariability. The measurement of catecholamines and total metanephrines after sleep is a viable approach for the exclusion of pheochromocytoma, as overnight urine collections completely differentiated patients with pheochromocytoma from hypertensive patients. Compared to 24-h results, overnight urinary norepinephrine levels provided a better diagnostic sensitivity and specificity (100% sensitivity and 98% specificity compared with 88% and 82%). Sleep urine samples simplify the collection protocol while avoiding the effects of stress and exercise.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.